Taltorvic 40mg Tablet
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Taltorvic was a proposed brand name for ridaforolimus, an mTOR-inhibitor cancer drug that has never been approved by any regulator.
- Ridaforolimus was studied in clinical trials for advanced soft-tissue and bone sarcoma.
- The FDA declined approval in June 2012 after an advisory committee voted against it, and the European marketing application was withdrawn in November 2012.
- There is no approved indication, prescribing information or marketed product under the name Taltorvic.
Side Effects
- Because ridaforolimus was never approved, there is no official label listing its side effects.
- Clinical trials reported effects typical of mTOR inhibitors, such as mouth sores and low blood counts.
- These findings come from research data and not from approved prescribing information.
Precautions & Warnings
- No approved product exists under this name, so do not obtain or take any product sold online as Taltorvic.
- If you were prescribed Taltorvic, contact your prescriber and pharmacist to confirm the intended medicine, as the name may be misheard, misspelled or outdated.
- No dosing, storage or safety guidance can be given because no regulatory label exists.
- Ask your oncologist which currently approved option suits your type of sarcoma.
Avoid Interactions
- No interaction information is available because there is no approved label for ridaforolimus.
- Tell your doctor and pharmacist about all medicines and supplements you take before starting any cancer treatment.
References
Frequently Asked Questions
No. "Taltorvic" was a proposed brand name for ridaforolimus, an mTOR-inhibitor cancer drug. The FDA refused approval in June 2012 after an advisory committee vote against it, and the EU marketing application was withdrawn in November 2012. No regulator has since approved it under any brand name.
No. Ridaforolimus is not sold or prescribed anywhere as an approved medicine; it exists only in past clinical trials for soft-tissue and bone sarcoma. There is no DailyMed, FDA or EMA product label for it, so no dosing, safety or storage information can be given for a real product.
In 2012 an FDA advisory committee found the trial evidence for ridaforolimus in advanced sarcoma insufficient to support approval, largely due to modest efficacy and safety concerns. The FDA issued a Complete Response Letter declining approval, and the developer withdrew the parallel European application soon after.
Contact your prescriber and pharmacist immediately, since no approved product exists under this name anywhere. Confirm the intended medicine and brand, as this may reflect a misheard, misspelled, or outdated name. Do not obtain or take any product sold online as "Taltorvic".
Ridaforolimus itself has no approved use anywhere, but other mTOR inhibitors, such as sirolimus-related agents, and several other targeted or chemotherapy-based sarcoma treatments are FDA- or EMA-approved for related indications. Ask your oncologist which currently approved option is appropriate for your specific type of soft-tissue or bone sarcoma.
Because ridaforolimus was never approved, there is no official label describing its side effects for general patient use. Clinical trials reported typical mTOR-inhibitor effects such as mouth sores and low blood counts, but these come from research data, not an approved prescribing information sheet.

Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.